Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study.
F. Herms(Délégation Paris 7), Nicole Basset‐Séguin(Inserm), Luc Haudebourg(Délégation Paris 7), S. Monestier(Hôpital de la Timone), Célèste Lebbé(Inserm), G. Jeudy(CHU Dijon Bourgogne), Jérôme Lambert(Délégation Paris 7), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), P. Vabres(Université de Bourgogne), Jean‐Jacques Grob, B. Guillot(Université de Montpellier), Nicolás Meyer(Université Toulouse III - Paul Sabatier), M. Bagot, Laurent Mortier, Nicolas Poulalhon(Hospices Civils de Lyon), M. Mouri(Roche (France)), Christine Mateus(Centre National de la Recherche Scientifique), Caroline Robert(Centre National de la Recherche Scientifique), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k